Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Lancet Infect Dis ; 24(7): 775-782, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38582089

ABSTRACT

BACKGROUND: Andes virus (ANDV) is a zoonotic Orthohantavirus leading to hantavirus cardiopulmonary syndrome. Although most transmissions occur through environmental exposure to rodent faeces and urine, rare person-to-person transmission has been documented, mainly for close contacts. This study investigates the presence and infectivity of ANDV in body fluids from confirmed cases and the duration of viraemia. METHODS: In this prospective study, 131 participants with confirmed ANDV infection were enrolled in Chile in a prospective study between 2008 and 2022. Clinical samples (buffy coat, plasma, gingival crevicular fluid [GCF], saliva, nasopharyngeal swabs [NPS], and urine) were collected weekly for 3 weeks together with clinical and epidemiological data. Samples were categorised as acute or convalescent (up to and after 16 days following onset of symptoms). Infectivity of positive fluids was assessed after the culture of samples on Vero E6 cells and use of flow cytometry assays to determine the production of ANDV nucleoprotein. FINDINGS: ANDV RNA was detected in 100% of buffy coats during acute phase, declining to 95% by day 17, and to 93% between days 23-29. ANDV RNA in GCF and saliva decreased from 30% and 12%, respectively, during the acute phase, to 12% and 11% during the convalescent phase. Successful infectivity assays of RT-qPCR-positive fluids, including GCF, saliva, NPS, and urine, were observed in 18 (42%) of 43 samples obtained during the acute phase of infection. After re-culture, the capacity to infect Vero E6 cells was maintained in 16 (89%) of 18 samples. Severity was associated with the presence of ANDV RNA in one or more fluids besides blood (odds ratio 2·58 [95% CI 1·42-5·18]). INTERPRETATION: ANDV infection is a systemic and viraemic infection, that affects various organs. The presence of infectious particles in body fluids contributes to our understanding of potential mechanisms for person-to-person transmission, supporting the development of preventive strategies. Detection of ANDV RNA in additional fluids at hospital admission is a predictor of disease severity. FUNDING: National Institutes of Health and Agencia de Investigación y Desarrollo. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.


Subject(s)
Hantavirus Infections , Orthohantavirus , Viremia , Virus Shedding , Humans , Prospective Studies , Male , Adult , Hantavirus Infections/transmission , Hantavirus Infections/epidemiology , Hantavirus Infections/virology , Female , Orthohantavirus/isolation & purification , Chile/epidemiology , Middle Aged , Young Adult , Adolescent , RNA, Viral , Animals , Child , Chlorocebus aethiops , Aged , Vero Cells
2.
PNAS Nexus ; 2(8): pgad259, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37649584

ABSTRACT

Epidemiological data across the United States of America illustrate health disparities in COVID-19 infection, hospitalization, and mortality by race/ethnicity. However, limited information is available from prospective observational studies in hospitalized patients, particularly for American Indian or Alaska Native (AI/AN) populations. Here, we present risk factors associated with severe COVID-19 and mortality in patients (4/2020-12/2021, n = 475) at the University of New Mexico Hospital. Data were collected on patient demographics, infection duration, laboratory measures, comorbidities, treatment(s), major clinical events, and in-hospital mortality. Severe disease was defined by COVID-related intensive care unit requirements and/or death. The cohort was stratified by self-reported race/ethnicity: AI/AN (30.7%), Hispanic (47.0%), non-Hispanic White (NHW, 18.5%), and Other (4.0%, not included in statistical comparisons). Despite similar timing of infection and comparable comorbidities, admission characteristics for AI/AN patients included younger age (P = 0.02), higher invasive mechanical ventilation requirements (P = 0.0001), and laboratory values indicative of more severe disease. Throughout hospitalization, the AI/AN group also experienced elevated invasive mechanical ventilation (P < 0.0001), shock (P = 0.01), encephalopathy (P = 0.02), and severe COVID-19 (P = 0.0002), consistent with longer hospitalization (P < 0.0001). Self-reported AI/AN race/ethnicity emerged as the highest risk factor for severe COVID-19 (OR = 3.19; 95% CI = 1.70-6.01; P = 0.0003) and was a predictor of in-hospital mortality (OR = 2.35; 95% CI = 1.12-4.92; P = 0.02). Results from this study highlight the disproportionate impact of COVID-19 on hospitalized AI/AN patients, who experienced more severe illness and associated mortality, compared to Hispanic and NHW patients, even when accounting for symptom onset and comorbid conditions. These findings underscore the need for interventions and resources to address health disparities in the COVID-19 pandemic.

3.
Lancet Infect Dis ; 23(9): e371-e382, 2023 09.
Article in English | MEDLINE | ID: mdl-37105214

ABSTRACT

Hantavirus infections are part of the broad group of viral haemorrhagic fevers. They are also recognised as a distinct model of an emergent zoonotic infection with a global distribution. Many factors influence their epidemiology and transmission, such as climate, environment, social development, ecology of rodent hosts, and human behaviour in endemic regions. Transmission to humans occurs by exposure to infected rodents in endemic areas; however, Andes hantavirus is unique in that it can be transmitted from person to person. As hantaviruses target endothelial cells, they can affect diverse organ systems; increased vascular permeability is central to pathogenesis. The main clinical syndromes associated with hantaviruses are haemorrhagic fever with renal syndrome (HFRS), which is endemic in Europe and Asia, and hantavirus cardiopulmonary syndrome (HCPS), which is endemic in the Americas. HCPS and HFRS are separate clinical entities, but they share several features and have many overlapping symptoms, signs, and pathogenic alterations. For HCPS in particular, clinical outcomes are highly associated with early clinical suspicion, access to rapid diagnostic testing or algorithms for presumptive diagnosis, and prompt transfer to a facility with critical care units. No specific effective antiviral treatment is available.


Subject(s)
Communicable Diseases , Hantavirus Infections , Hantavirus Pulmonary Syndrome , Hemorrhagic Fever with Renal Syndrome , Orthohantavirus , Humans , Hemorrhagic Fever with Renal Syndrome/diagnosis , Hemorrhagic Fever with Renal Syndrome/epidemiology , Hemorrhagic Fever with Renal Syndrome/therapy , Endothelial Cells/pathology , Hantavirus Pulmonary Syndrome/diagnosis , Hantavirus Pulmonary Syndrome/drug therapy , Hantavirus Pulmonary Syndrome/epidemiology , Hantavirus Infections/diagnosis , Hantavirus Infections/epidemiology , Hantavirus Infections/therapy
5.
Exp Biol Med (Maywood) ; 247(14): 1253-1263, 2022 07.
Article in English | MEDLINE | ID: mdl-35491994

ABSTRACT

Epidemiological data across the United States show health disparities in COVID-19 infection, hospitalization, and mortality by race/ethnicity. While the association between elevated SARS-CoV-2 viral loads (VLs) (i.e. upper respiratory tract (URT) and peripheral blood (PB)) and increased COVID-19 severity has been reported, data remain largely unavailable for some disproportionately impacted racial/ethnic groups, particularly for American Indian or Alaska Native (AI/AN) populations. As such, we determined the relationship between SARS-CoV-2 VL dynamics and disease severity in a diverse cohort of hospitalized patients. Results presented here are for study participants (n = 94, ages 21-88 years) enrolled in a prospective observational study between May and October 2020 who had SARS-CoV-2 viral clades 20A, C, and G. Based on self-reported race/ethnicity and sample size distribution, the cohort was stratified into two groups: (AI/AN, n = 43) and all other races/ethnicities combined (non-AI/AN, n = 51). SARS-CoV-2 VLs were quantified in the URT and PB on days 0-3, 6, 9, and 14. The strongest predictor of severe COVID-19 in the study population was the mean VL in PB (OR = 3.34; P = 2.00 × 10-4). The AI/AN group had the following: (1) comparable co-morbidities and admission laboratory values, yet more severe COVID-19 (OR = 4.81; P = 0.014); (2) a 2.1 longer duration of hospital stay (P = 0.023); and (3) higher initial and cumulative PB VLs during severe disease (P = 0.025). Moreover, self-reported race/ethnicity as AI/AN was the strongest predictor of elevated PB VLs (ß = 1.08; P = 6.00 × 10-4) and detection of SARS-CoV-2 in PB (hazard ratio = 3.58; P = 0.004). The findings presented here suggest a strong relationship between PB VL (magnitude and frequency) and severe COVID-19, particularly for the AI/AN group.


Subject(s)
COVID-19 , Adult , Aged , Aged, 80 and over , COVID-19/epidemiology , Ethnicity , Humans , Middle Aged , Racial Groups , SARS-CoV-2 , United States/epidemiology , Young Adult
6.
J Virol ; 95(23): e0153421, 2021 11 09.
Article in English | MEDLINE | ID: mdl-34549977

ABSTRACT

Sin Nombre orthohantavirus (SNV), a negative-sense, single-stranded RNA virus that is carried and transmitted by the North American deer mouse Peromyscus maniculatus, can cause infection in humans through inhalation of aerosolized excreta from infected rodents. This infection can lead to hantavirus cardiopulmonary syndrome (HCPS), which has an ∼36% case-fatality rate. We used reverse transcriptase quantitative PCR (RT-qPCR) to confirm SNV infection in a patient and identified SNV in lung tissues in wild-caught rodents from potential sites of exposure. Using viral whole-genome sequencing (WGS), we identified the likely site of transmission and discovered SNV in multiple rodent species not previously known to carry the virus. Here, we report, for the first time, the use of SNV WGS to pinpoint a likely site of human infection and identify SNV simultaneously in multiple rodent species in an area of known host-to-human transmission. These results will impact epidemiology and infection control for hantaviruses by tracing zoonotic transmission and investigating possible novel host reservoirs. IMPORTANCE Orthohantaviruses cause severe disease in humans and can be lethal in up to 40% of cases. Sin Nombre orthohantavirus (SNV) is the main cause of hantavirus disease in North America. In this study, we sequenced SNV from an infected patient and wild-caught rodents to trace the location of infection. We also discovered SNV in rodent species not previously known to carry SNV. These studies demonstrate for the first time the use of virus sequencing to trace the transmission of SNV and describe infection in novel rodent species.


Subject(s)
Disease Reservoirs/virology , Hantavirus Pulmonary Syndrome/transmission , Hantavirus Pulmonary Syndrome/veterinary , Hantavirus Pulmonary Syndrome/virology , Rodent Diseases/transmission , Rodent Diseases/virology , Rodentia/virology , Sin Nombre virus , Animals , Antibodies, Viral , Base Sequence , Female , Orthohantavirus/genetics , Hantavirus Infections/genetics , Hantavirus Infections/transmission , Hantavirus Infections/veterinary , Hantavirus Pulmonary Syndrome/epidemiology , Humans , Lung , Male , Mice , North America , Peromyscus/virology , Prevalence , RNA, Viral/genetics , Rodent Diseases/epidemiology , Sin Nombre virus/genetics , White People , Whole Genome Sequencing
7.
Int J Infect Dis ; 110: 466-468, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34271201

ABSTRACT

OBJECTIVES: To determine the relative frequency and prognosis value of proteinuria in hantavirus cardiopulmonary syndrome (HCPS) due to Andes virus. METHODS: This observational analytical study prospectively obtained data from patients admitted to 12 health centers in nine Chilean cities between 2001 and 2018. Only patients with confirmed Andes virus HCPS and laboratory characterization that included qualitative proteinuria determination at admission were considered. RESULTS: The database involved 175 patients, 95 of them had a measurement of urine protein at the time of hospital admission. They were mainly male (71%) and the median age was 35 [22-47] years. Median duration of the febrile prodromal time was 5 [4-7] days. Hospital length of stay and hospital mortality rate were 10 [7-14] days and 21.1%, respectively. Seventy-three patients (77%) were identified with proteinuria at admission, which was associated with increased mortality rate (26% versus 5%, p=0.036) and the relative risk was 1.3 [1.1-1.6], p=0.002. CONCLUSIONS: Proteinuria is a frequent finding in patients with HCPS, which is associated with a higher mortality rate.


Subject(s)
Communicable Diseases , Hantavirus Infections , Hantavirus Pulmonary Syndrome , Orthohantavirus , Adult , Hantavirus Pulmonary Syndrome/complications , Hantavirus Pulmonary Syndrome/diagnosis , Hantavirus Pulmonary Syndrome/epidemiology , Humans , Male , Proteinuria/epidemiology
8.
Materials (Basel) ; 14(10)2021 May 20.
Article in English | MEDLINE | ID: mdl-34065263

ABSTRACT

In this work, the use of Time of Flight Secondary Ion Mass Spectrometry (TOF-SIMS) was explored as a technique for monitoring the interfacial retro Diels-Alder (retro DA) reaction occurring on well-controlled self-assembled monolayers (SAMs). A molecule containing a Diels-Alder (DA) adduct was grafted on to the monolayers, then the surface was heated at different temperatures to follow the reaction conversion. A TOF-SIMS analysis of the surface allowed the detection of a fragment from the molecule, which is released from the surface when retro DA reaction occurs. Hence, by monitoring the decay of this fragment's peak integral, the reaction conversion could be determined in function of the time and for different temperatures. The viability of this method was then discussed in comparison with the results obtained by 1H NMR spectroscopy.

9.
Article in English | MEDLINE | ID: mdl-33042854

ABSTRACT

Andes orthohantavirus (ANDV) is the etiologic agent of hantavirus cardiopulmonary syndrome (HCPS), which has a case fatality rate around 35%, with no effective treatment or vaccine available. ANDV neutralizing antibody (NAb) measurements are important for the evaluation of the immune response following infection, vaccination, or passive administration of investigational monoclonal or polyclonal antibodies. The standard assay for NAb measurement is a focus reduction neutralization test (FRNT) featuring live ANDV and must be completed under biosafety level (BSL)-3 conditions. In this study, we compared neutralization assays featuring infectious ANDV or vesicular stomatitis virus (VSV) pseudovirions decorated with ANDV glycoproteins for their ability to measure anti-ANDV NAbs from patient samples. Our studies demonstrate that VSV pseudovirions effectively measure NAb from clinical samples and have greater sensitivity compared to FRNT with live ANDV. Importantly, the pseudovirus assay requires less labor and sample materials and can be conducted at BSL-2.


Subject(s)
Hantavirus Infections , Orthohantavirus , Antibodies, Neutralizing , Antibodies, Viral , Hantavirus Infections/diagnosis , Humans , Neutralization Tests
10.
J Infect Dis ; 222(10): 1620-1628, 2020 10 13.
Article in English | MEDLINE | ID: mdl-32779705

ABSTRACT

BACKGROUND: Convalescent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers in donor plasma and their impact in patients with acute COVID-19 remains largely undetermined. We measured NAb titers in CP and in patients with acute COVID-19 before and after transfusion through the traditional Food and Drug Administration investigational new drug pathway. METHODS: We performed a single-arm interventional trial measuring NAb and total antibody titers before and after CP transfusion over a 14-day period in hospitalized patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection. RESULTS: NAb titers in the donor CP units were low (<1:40 to 1:160) and had no effect on recipient neutralizing activity 1 day after transfusion. NAb titers were detected in 6 of 12 patients on enrollment and in 11 of 12 at ≥2 time points. Average titers peaked on day 7 and declined toward day 14 (P = .004). Nab titers and immunoglobulin G levels were correlated in donor plasma units (ρ = 0.938; P < .001) and in the cumulative patient measures (ρ = 0.781; P < .001). CONCLUSIONS: CP infusion did not alter recipient NAb titers. Prescreening of CP may be necessary for selecting donors with high titers of neutralizing activity for infusion into patients with COVID-19. CLINICAL TRIALS REGISTRATION: NCT04434131.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Betacoronavirus/immunology , Blood Donors , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , Adult , Aged , Aged, 80 and over , Betacoronavirus/genetics , COVID-19 , Cohort Studies , Coronavirus Infections/virology , Female , Humans , Immunization, Passive , Immunoglobulin G/blood , Male , Middle Aged , New Mexico/epidemiology , Pandemics , Pneumonia, Viral/virology , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/immunology , Treatment Outcome , COVID-19 Serotherapy
11.
Emerg Infect Dis ; 26(8): 1885-1888, 2020 08.
Article in English | MEDLINE | ID: mdl-32687024

ABSTRACT

Andes virus (ANDV) is the only hantavirus transmitted between humans through close contact. We detected the genome and proteins of ANDV in breast milk cells from an infected mother in Chile who transmitted the virus to her child, suggesting gastrointestinal infection through breast milk as a route of ANDV person-to-person transmission.


Subject(s)
Hantavirus Infections , Orthohantavirus , Child , Chile/epidemiology , Female , Humans , Infectious Disease Transmission, Vertical , Milk, Human
12.
Rev Chilena Infectol ; 36(4): 428-432, 2019 Aug.
Article in Spanish | MEDLINE | ID: mdl-31859765

ABSTRACT

BACKGROUND: Hantavirus cardiopulmonary syndrome (HCPS) is caused by new world hantaviruses, among which Andes hantavirus (ANDV) is endemic to Chile and Southern Argentina. The disease caused by ANDV produces plasma leakage leading to enhanced vascular permeability and has a high case fatality rate (35%), mainly due to respiratory failure, pulmonary edema and myocardial dysfunction, hypoperfusion and shock. Host sociodemographic and genetic factors might influence the course and outcome of the disease. Yet, they have not been thoroughly characterized. AIM: To evaluate sociodemographic factors as risk factors in severity of HCPS. PATIENTS AND METHODS: Study period: 2004-20013, attending in eight collaborative centers, etiological diagnosis was performed by serology or molecular biology, mild and severe HCPS were compared.139 Chilean patients were analyzed, 64 (46%) with severe disease among which 12 (19 %) died. RESULTS: European ethnicity had 5,1 times higher risk than Amerindian ethnic group to develop a severe HCPS, greater seriousness that was also associated with an urban residence. CONCLUSION: It was observed that ethnicity and type of residence were significant risk factors for HCPS severity. Hypotheses explaining these findings are discussed.


Subject(s)
Hantavirus Pulmonary Syndrome/mortality , Adolescent , Adult , Aged , Child , Chile/epidemiology , Female , Humans , Male , Middle Aged , Risk Factors , Severity of Illness Index , Socioeconomic Factors , Young Adult
13.
Viruses ; 11(9)2019 09 12.
Article in English | MEDLINE | ID: mdl-31547341

ABSTRACT

Small mammals present in areas where hantavirus cardiopulmonary syndrome (HCPS) cases had occurred in central and southern Chile were captured and analyzed to evaluate the abundance of rodents and seroprevalence rates of antibodies to Andes orthohantavirus (ANDV). Sampling areas ranged from the Coquimbo to Aysén regions (30-45° S approx.) regions. Ninety-two sites in peridomestic and countryside areas were evaluated in 19 years of sampling. An antibody against ANDV was detected by strip immunoassay in 58 of 1847 specimens captured using Sherman traps. Of the eleven species of rodents sampled, Abrothrix olivacea, Oligoryzomys longicaudatus and Abrothrix hirta were the most frequently trapped. O. longicaudatus had the highest seropositivity rate, and by logistic regression analysis, O. longicaudatus of at least 60 g had 80% or higher probability to be seropositive. Sex, age and wounds were significantly related to seropositivity only for O. longicaudatus. Across administrative regions, the highest seropositivity was found in the El Maule region (34.8-36.2° S), and the highest number of HCPS cases was registered in the Aysén region. Our results highlight the importance of long term and geographically extended studies, particularly for highly fluctuating pathogens and their reservoirs, to understand the implications of the dynamics and transmission of zoonotic diseases in human populations.


Subject(s)
Antibodies, Viral/blood , Disease Reservoirs/virology , Hantavirus Infections/veterinary , Rodent Diseases/virology , Rodentia/virology , Zoonoses/transmission , Animal Distribution , Animals , Chile/epidemiology , Female , Geography , Orthohantavirus , Hantavirus Infections/epidemiology , Hantavirus Pulmonary Syndrome/transmission , Humans , Male , Rodent Diseases/epidemiology , Rodent Diseases/transmission , Seroepidemiologic Studies , Zoonoses/epidemiology , Zoonoses/virology
14.
Viruses ; 11(8)2019 07 30.
Article in English | MEDLINE | ID: mdl-31366116

ABSTRACT

BACKGROUND: Hantavirus cardiopulmonary syndrome (HCPS) has a mortality up to 35-40% and its treatment is mainly supportive. A variable to predict progression from mild to severe disease is unavailable. This study was performed in patients with documented infection by Andes orthohantavirus, and the aim was to find a simple variable to predict progression to moderate/severe HCPS in patients with mild disease at admission. METHODS: We performed a retrospective analysis of 175 patients between 2001 and 2018. Patients were categorized into mild, moderate, and severe disease according to organ failure and advanced support need at hospital admission (e.g., mechanical ventilation, vasopressors). Progression to moderate/severe disease was defined accordingly. Clinical and laboratory variables associated with progression were explored. RESULTS: Forty patients with mild disease were identified; 14 of them progressed to moderate/severe disease. Only platelet count was different between those who progressed versus those that did not (37 (34-58) vs. 83 (64-177) K/mm3, p < 0.001). A ROC curve analysis showed an AUC = 0.889 (0.78-1.0) p < 0.001, with a platelet count greater than 115K /mm3 ruling out progression to moderate/severe disease. CONCLUSIONS: In patients with mild disease at presentation, platelet count could help to define priority of evacuation to tertiary care centers.


Subject(s)
Hantavirus Infections/blood , Hantavirus Infections/complications , Hantavirus Pulmonary Syndrome/blood , Thrombocytopenia/complications , Adult , Chile , Disease Progression , Female , Hantavirus Infections/classification , Humans , Male , Middle Aged , Platelet Count , ROC Curve , Retrospective Studies , Thrombocytopenia/virology , Young Adult
15.
Rev. chil. infectol ; 36(4): 428-432, ago. 2019. tab
Article in Spanish | LILACS | ID: biblio-1042658

ABSTRACT

Resumen Introducción: El síndrome cardiopulmonar por hantavirus (SCPH) es causado en Chile y en el sur de Argentina por el Andes hantavirus (ANDV), el que es endémico en esta zona. La enfermedad causada por ANDV produce un aumento de permeabilidad vascular y filtración de plasma con una alta tasa de letalidad (35%), debido principalmente a insuficiencia respiratoria por edema pulmonar y al desarrollo en los casos graves de compromiso miocárdico, hipoperfusión y shock. Aunque se sabe que los factores socio-demográficos del hospedero pueden influir en el curso y el resultado de la enfermedad, estos no se han caracterizado previamente en la población chilena. Objetivo: Evaluar la relación entre los factores socio-demográficos y la gravedad del SCPH. Pacientes y Métodos: Período de análisis 2004-20013, pacientes atendidos en ocho centros colaboradores, diagnóstico etiológico serológico o por biología molecular, se comparan SCPH leve y grave. Se analizaron 139 pacientes chilenos, 64 (46%) con enfermedad grave, entre los cuales 12 murieron (19%). Resultados: La etnia europea tuvo un riesgo 5,1 veces mayor de desarrollar un SCPH grave que la etnia amerindia, gravedad mayor que también se asoció a una residencia urbana. Conclusiones: Se observó una asociación estadísticamente significativa entre etnia, lugar de residencia y evolución de SCPH. Se discuten hipótesis que expliquen estos hallazgos.


Background: Hantavirus cardiopulmonary syndrome (HCPS) is caused by new world hantaviruses, among which Andes hantavirus (ANDV) is endemic to Chile and Southern Argentina. The disease caused by ANDV produces plasma leakage leading to enhanced vascular permeability and has a high case fatality rate (35%), mainly due to respiratory failure, pulmonary edema and myocardial dysfunction, hypoperfusion and shock. Host sociodemographic and genetic factors might influence the course and outcome of the disease. Yet, they have not been thoroughly characterized. Aim: To evaluate sociodemographic factors as risk factors in severity of HCPS. Patients and Methods: Study period: 2004-20013, attending in eight collaborative centers, etiological diagnosis was performed by serology or molecular biology, mild and severe HCPS were compared.139 Chilean patients were analyzed, 64 (46%) with severe disease among which 12 (19 %) died. Results: European ethnicity had 5,1 times higher risk than Amerindian ethnic group to develop a severe HCPS, greater seriousness that was also associated with an urban residence. Conclusion: It was observed that ethnicity and type of residence were significant risk factors for HCPS severity. Hypotheses explaining these findings are discussed.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Young Adult , Hantavirus Pulmonary Syndrome/mortality , Socioeconomic Factors , Severity of Illness Index , Chile/epidemiology , Risk Factors
16.
Viruses ; 11(8)2019 07 25.
Article in English | MEDLINE | ID: mdl-31349540

ABSTRACT

Andes orthohantavirus (ANDV) is an important human pathogen causing hantavirus cardiopulmonary syndrome (HCPS) with a fatality rate of 30% in Chile. Around 60% of all cases have a severe clinical course, while the others have a mild clinical course. The main goal of this study was to understand if the genetic variation of patients is associated with the clinical course they develop after ANDV infection. For this, the frequency of copy number variants (CNVs, i.e., deletions and duplications) was studied in 195 patients, 88 with mild and 107 with severe HCPS. CNVs were called from intensity data of the Affymetrix Genome-Wide SNP Array 6.0. The analysis of the data was performed with PennCNV, ParseCNV and R softwares; Results: a deletion of 19, 416 bp in the q31.3 region of chromosome 1 is found more frequently in severe patients (p < 0.05). This region contains Complement Factor H Related (CFHR1) and CFHR3 genes, regulators of the complement cascade. A second deletion of 1.81 kb located in the p13 region of chr20 was significantly more frequent in mild patients (p < 0.05). This region contains the SIRPB1 gene, which participates in the innate immune response, more specifically in neutrophil trans-epithelial migration. Both deletions are associated with the clinical course of HCPS, the first being a risk factor and the second being protective. The participation of genes contained in both deletions in ANDV infection pathophysiology deserves further investigation.


Subject(s)
Genetic Predisposition to Disease , Hantavirus Infections/genetics , Hantavirus Infections/immunology , Immunity, Innate/genetics , Sequence Deletion , Aged , Chile , Complement Factor H/genetics , Complement Factor H/immunology , DNA Copy Number Variations , Female , Genetic Variation , Genotype , Orthohantavirus , Humans , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Prospective Studies , Receptors, Cell Surface/genetics , Receptors, Cell Surface/immunology
17.
Viruses ; 11(2)2019 02 20.
Article in English | MEDLINE | ID: mdl-30791508

ABSTRACT

The AndesOrthohantavirus (ANDV), which causes the hantavirus cardiopulmonary syndrome, enters cells via integrins, and a change from leucine to proline at residue 33 in the PSI domain (L33P), impairs ANDV recognition. We assessed the association between this human polymorphism and ANDV infection. We defined susceptible and protective genotypes as "TT" (coding leucine) and "CC" (coding proline), respectively. TT was present at a rate of 89.2% (66/74) among the first cohort of ANDV cases and at 60% (63/105) among exposed close-household contacts, who remained uninfected (p < 0.05). The protective genotype (CC) was absent in all 85 ANDV cases, in both cohorts, and was present at 11.4% of the exposed close-household contacts who remained uninfected. Logistic regression modeling for risk of infection had an OR of 6.2⁻12.6 (p < 0.05) in the presence of TT and well-known ANDV risk activities. Moreover, an OR of 7.3 was obtained when the TT condition was analyzed for two groups exposed to the same environmental risk. Host genetic background was found to have an important role in ANDV infection susceptibility, in the studied population.


Subject(s)
Genetic Predisposition to Disease , Hantavirus Infections/genetics , Integrin alphaVbeta3/genetics , Orthohantavirus , Polymorphism, Single Nucleotide , Adult , Family Characteristics , Female , Genotype , Humans , Leucine/genetics , Male , Proline/genetics , Prospective Studies , Risk Assessment , Risk Factors
18.
J Phys Chem B ; 121(27): 6646-6654, 2017 07 13.
Article in English | MEDLINE | ID: mdl-28628747

ABSTRACT

During the past decade, synthesizing silver nanoparticles (Ag NPs) by liquid phase-pulsed laser ablation (LP-PLA) has attracted a lot of attention. Basically, this technique allows producing various metallic nanoparticles with controlled size, shape, composition, or surroundings in several liquids (i.e., water, ethanol, acetone, toluene, and so forth). Recently, such processes have been studied in liquid organic monomer such as methyl methacrylate (MMA). However, the influence of the laser parameters on the materials synthesized in such reactive liquid and their features were not fully investigated so far. Here we investigate the LP-PLA of silver in two different but rather similar acrylate monomers: dodecyl acrylate (DOCA) and 1H,1H,2H,2H perfluorodecyl acrylate (PFDA). The influence of the fluence and the number of pulses on the production, size, and morphology of the materials has been examined. First, factorial design experiments have been achieved in order to determine the weight of the laser parameters in each precursor. This study shows two highly different behaviors in function of the monomer where the process took place. This has been explained by the plasma plume confinement and/or the "interpulses" self-absorption of the particles by the laser beam. The formation of graphite around the synthesized AgNPs has been highlighted by Raman spectroscopy at low number of pulses. Nevertheless, increasing the number of pulses could lead to three phenomenon depending on the fluence and the used monomer: degradation of the matrix, conservation of the matrix with changes in AgNPs size and distribution, or sustainment of the matrix with any changes in the particles properties. So the surrounding, the size, and stability could be triggered by adjusting these parameters. This paper does highlight that LP-PLA is a powerful technique to provide AgNPs in acrylate monomer with a good control of their features.

19.
Hum Vaccin Immunother ; 13(4): 808-815, 2017 04 03.
Article in English | MEDLINE | ID: mdl-27830976

ABSTRACT

Andes hantavirus cardiopulmonary syndrome, transmitted by Oligoryzomys longicaudatus, has no approved treatment, a case fatality rate of 35%, and documented person-to-person transmission. An Andes vaccine, highly needed for prevention, is in development. We aimed to evaluate knowledge, attitudes and practices (KAP) regarding hantavirus disease and willingness to participate in a future Andes vaccine trials through a cross sectional face-to-face oral survey of a randomly selected adult sample from 2 rural communes in southern Chile. Human subjects approval was obtained from our institutional IRBs, and participants signed informed consent. We enrolled 319 subjects from Corral and 321 from Curarrehue; 98% had heard about hantavirus disease and its reservoir but only half knew about transmission, symptoms and prevention. Participants fear the disease but are only partially aware of their own risk. One third of participants reported presence of rodents inside their homes. Despite moderate confidence in their health system, most subjects perceived vaccines as beneficial, and 93% would accept an approved hantavirus vaccine. Half would agree to participate in a vaccine trial and 29% would allow their children to participate. Motivations to participate were mainly altruistic, while risk perception was the main reason for declining. Knowledge about hantavirus disease and prevention practices require reinforcement, and a vaccine trial seems feasible in these populations.


Subject(s)
Clinical Trials as Topic , Hantavirus Infections/epidemiology , Hantavirus Infections/prevention & control , Health Knowledge, Attitudes, Practice , Patient Acceptance of Health Care , Vaccination/psychology , Viral Vaccines/administration & dosage , Adult , Aged , Aged, 80 and over , Animals , Chile/epidemiology , Cross-Sectional Studies , Female , Orthohantavirus/immunology , Orthohantavirus/pathogenicity , Humans , Interviews as Topic , Male , Middle Aged , Rural Population , Young Adult
20.
Antivir Ther ; 20(4): 377-86, 2015.
Article in English | MEDLINE | ID: mdl-25316807

ABSTRACT

BACKGROUND: In Chile, Andes virus (ANDV) is the sole aetiological agent of hantavirus cardiopulmonary syndrome (HCPS) with mean annual incidence of 55 cases, 32% case fatality rate (CFR) and no specific treatment. Neutralizing antibody (NAb) titres at hospital admission correlate inversely with HCPS severity. We designed an open trial to explore safety and efficacy and evaluate pharmacokinetics of immune plasma as a treatment strategy for this disease. METHODS: We performed plasmapheresis on donors at least 6 months after HCPS and measured NAb titres through a focus-reduction neutralization test. Subjects admitted to 10 study sites with suspected/confirmed HCPS were eligible for treatment with immune plasma by intravenous infusion at an ANDV NAb dose of 5,000 U/kg. HCPS was confirmed through immunoglobulin M serology or reverse transcriptase-PCR. The main outcome was mortality within 30 days. RESULTS: From 2008-2012, we enrolled and treated 32 cases and confirmed HCPS in 29. CFR of hantavirus plasma-treated cases was 4/29 (14%); CFR of non-treated cases in the same period in Chile was 63/199 (32%; P=0.049, OR=0.35, CI=0.12, 0.99); CFR of non-treated cases at the same study sites between 2005-2012 was 18/66 (27%; (P=0.15, OR=0.43, CI=0.14, 1.34) and CFR in a previous methylprednisolone treatment study was 20/60 (33%; P=0.052, OR=0.32, CI=0.10, 1.00). We detected no serious adverse events associated to plasma infusion. Plasma NAb titres reached in recipients were variable and viral load remained stable. CONCLUSIONS: Human ANDV immune plasma infusion appears safe for HCPS. We observed a decrease in CFR in treated cases with borderline significance that will require further studies for confirmation.


Subject(s)
Antibodies, Neutralizing/therapeutic use , Antibodies, Viral/therapeutic use , Hantavirus Infections/therapy , Immune Sera/pharmacology , RNA, Viral/antagonists & inhibitors , Adult , Female , Glucocorticoids/therapeutic use , Orthohantavirus/drug effects , Orthohantavirus/growth & development , Orthohantavirus/immunology , Hantavirus Infections/immunology , Hantavirus Infections/mortality , Hantavirus Infections/virology , Heart/drug effects , Heart/physiopathology , Heart/virology , Humans , Lung/drug effects , Lung/immunology , Lung/pathology , Lung/virology , Male , Methylprednisolone/therapeutic use , Middle Aged , Neutralization Tests , Plasmapheresis , RNA, Viral/blood , RNA, Viral/immunology , Severity of Illness Index , Survival Analysis , Syndrome , Viral Load/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...